These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 10535477)

  • 1. Case report: Occurrence of hepatocellular carcinoma 4.5 years after successful treatment with virus clearance for chronic hepatitis C.
    Miyano S; Togashi H; Shinzawa H; Sugahara K; Matsuo T; Takeda Y; Saito K; Saito T; Ishiyama S; Kaneko M; Takahashi T
    J Gastroenterol Hepatol; 1999 Sep; 14(9):928-30. PubMed ID: 10535477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term responders without eradication of hepatitis C virus after interferon therapy: characterization of clinical profiles and incidence of hepatocellular carcinoma.
    Yabuuchi I; Imai Y; Kawata S; Tamura S; Noda S; Inada M; Maeda Y; Shirai Y; Fukuzaki T; Kaji I; Ishikawa H; Matsuda Y; Nishikawa M; Seki K; Matsuzawa Y
    Liver; 2000 Jul; 20(4):290-5. PubMed ID: 10959807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocellular carcinoma developed in a patient with chronic hepatitis C after the disappearance of hepatitis C virus due to interferon therapy.
    Inoue M; Ohhira M; Ohtake T; Matsumoto A; Kawashima T; Fujimoto Y; Hasebe C; Ono M; Kohgo Y
    Hepatogastroenterology; 1999; 46(28):2554-60. PubMed ID: 10522040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival.
    Shiratori Y; Ito Y; Yokosuka O; Imazeki F; Nakata R; Tanaka N; Arakawa Y; Hashimoto E; Hirota K; Yoshida H; Ohashi Y; Omata M;
    Ann Intern Med; 2005 Jan; 142(2):105-14. PubMed ID: 15657158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma--A retrospective multicenter study.
    Harada N; Hiramatsu N; Oze T; Tatsumi T; Hayashi N; Takehara T
    J Med Virol; 2015 Jul; 87(7):1199-206. PubMed ID: 25772024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Summaries for patients. Long-term effects of antiviral treatment for hepatitis C.
    Ann Intern Med; 2005 Jan; 142(2):I51. PubMed ID: 15657153
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.
    Marcellin P; Boyer N; Gervais A; Martinot M; Pouteau M; Castelnau C; Kilani A; Areias J; Auperin A; Benhamou JP; Degott C; Erlinger S
    Ann Intern Med; 1997 Nov; 127(10):875-81. PubMed ID: 9382365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective study of a high-intensity interferon-alpha regimen for chronic hepatitis C virus genotype 1b infection.
    Toyoda H; Kumada T; Nakano S; Takeda I; Sugiyama K; Kiriyama S; Tanikawa M; Sone Y; Hisanaga Y; Hayashi K
    Hepatogastroenterology; 2002; 49(48):1619-24. PubMed ID: 12397749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development.
    Kashiwagi K; Furusyo N; Kubo N; Nakashima H; Nomura H; Kashiwagi S; Hayashi J
    J Infect Chemother; 2003 Dec; 9(4):333-40. PubMed ID: 14691655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrence rate and prognosis of patients with hepatocellular carcinoma that developed after elimination of hepatitis C virus RNA by interferon therapy. A closed cohort study including matched control patients.
    Ikeda K; Kobayashi M; Saitoh S; Someya T; Hosaka T; Akuta N; Suzuki F; Tsubota A; Suzuki Y; Arase Y; Kumada H
    Oncology; 2003; 65(3):204-10. PubMed ID: 14657593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of small hepatocellular carcinoma 80 months after clearance of hepatitis C virus with interferon therapy.
    Yamada M; Ichikawa M; Matsubara A; Ishiguro Y; Yamada M; Yokoi S
    Eur J Gastroenterol Hepatol; 2000 Sep; 12(9):1029-32. PubMed ID: 11007142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case report: development of hepatocellular carcinoma in a patient with chronic hepatitis C infection after a complete and sustained response to interferon-alpha.
    Hirashima N; Mizokami M; Orito E; Koide T; Itazu I; Kumada K; Sakakibara K; Kano H; Lau JY
    J Gastroenterol Hepatol; 1996 Oct; 11(10):955-8. PubMed ID: 8912134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of hepatocellular carcinoma after clearance of hepatitis C virus with interferon therapy.
    Tong MJ; Lai LP; Murakami-Mori K
    West J Med; 1997 Aug; 167(2):103-5. PubMed ID: 9291751
    [No Abstract]   [Full Text] [Related]  

  • 15. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.
    Tokita H; Fukui H; Tanaka A; Kamitsukasa H; Yagura M; Harada H; Okamoto H
    J Gastroenterol Hepatol; 2005 May; 20(5):752-8. PubMed ID: 15853990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
    Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type C chronic hepatitis with the discovery of a small hepatocellular carcinoma 7 years after successful interferon therapy.
    Tomimatsu M; Endo H; Kitazawa M; Iga D; Fujimoto T; Ohkawa S; Kajiyama H; Katagiri S; Harada N; Yamamoto M; Takasaki K
    J Gastroenterol; 2003; 38(4):395-8. PubMed ID: 12743782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C.
    Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):122-8. PubMed ID: 16706823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resected cases of hepatocellular carcinoma detected after interferon therapy for chronic hepatitis C.
    Kubo S; Nishiguchi S; Tamori A; Hirohashi K; Tanaka H; Tsukamoto T; Shuto T; Kuroki T; Kinoshita H
    Hepatogastroenterology; 2000; 47(34):1100-2. PubMed ID: 11020887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy.
    Tsuda N; Yuki N; Mochizuki K; Nagaoka T; Yamashiro M; Omura M; Hikiji K; Kato M
    J Med Virol; 2004 Nov; 74(3):406-13. PubMed ID: 15368524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.